



Miltenyi Biotec

Reference list

CD271⁺ Mesenchymal Stromal Cells

CliniMACS[®] CD271 Product line

Contents

- A) Background information
- B) Preclinical evaluation

A) Background information

Anti-L-NGFR and -CD34 monoclonal antibodies identify multipotent mesenchymal stem cells in human adipose tissue.

Quirici N, Scavullo C, de Girolamo L, Lopa S, Arrigoni E, Delilliers GL, Brini AT.
Stem Cells Dev. 2010 Jun;19(6):915-25.

Prospective isolation of mesenchymal stem cells from multiple mammalian species using cross-reacting anti-human monoclonal antibodies.

Rozemuller H, Prins HJ, Naaijken B, Staal J, Bühring HJ, Martens AC.
Stem Cells Dev. 2010 Dec;19(12):1911-21. Epub 2010 Aug 12.

The CD271 expression could be alone for establisher phenotypic marker in Bone Marrow derived mesenchymal stem cells.

Flores-Torales E, Orozco-Barocio A, Gonzalez-Ramella OR, Carrasco-Yalan A, Gazarian K, Cuneo-Pareto S.
Folia Histochem Cytobiol. 2010 Dec 1;48(4):682-6.

CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties.

Kuçi S, Kuçi Z, Kreyenberg H, Deak E, Pütsch K, Huenecke S, Amara C, Koller S, Rettinger E, Grez M, Koehl U, Latifi-Pupovci H, Henschler R, Tonn T, von Laer D, Klingebiel T, Bader P.
Haematologica. 2010 Apr;95(4):651-9. Epub 2010 Feb 23.

Advantage of mesenchymal stem cells (MSC) expansion directly from purified bone marrow CD105⁺ and CD271⁺ cells.

Jarocho D, Lukasiewicz E, Majka M.
Folia Histochem Cytobiol. 2008;46(3):307-14.

Novel markers for the prospective isolation of human MSC.

Bühring HJ, Battula VL, Tremel S, Schewe B, Kanz L, Vogel W.
Ann N Y Acad Sci. 2007 Jun;1106:262-71. Epub 2007 Mar 29.

Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies.

Quirici N, Soligo D, Bossolasco P, Servida F, Lumini C, Delilliers GL.
Exp Hematol. 2002 Jul;30(7):783-91.

B) Preclinical evaluation

Bone Marrow Cells Immunomagnetically Selected For CD271⁺ Antigen Promote In Vitro the Repair of Articular Cartilage Defects.

Hermida-Gómez T, Fuentes-Boquete I, Gimeno-Longas MJ, Muiños-López E, Díaz-Prado S, de Toro FJ, Blanco FJ.
Tissue Eng Part A. 2011 Apr;17(7-8):1169-79. Epub 2011 Feb 7.

Large-scale extraction and characterization of CD271⁺ multipotent stromal cells from trabecular bone in health and osteoarthritis: implications for bone regeneration strategies based on uncultured or minimally cultured multipotent stromal cells.

Jones E, English A, Churchman SM, Kouroupis D, Boxall SA, Kinsey S, Giannoudis PG, Emery P, McGonagle D.
Arthritis Rheum. 2010 Jul;62(7):1944-54. Erratum in: Arthritis Rheum. 2010 Oct;62(10):3005.

Selection of CD271(+) cells and human AB serum allows a large expansion of mesenchymal stromal cells from human bone marrow.

Poloni A, Maurizi G, Rosini V, Mondini E, Mancini S, Discepoli G, Biasio S, Battaglini G, Felicetti S, Berardinelli E, Serrani F, Leoni P.
Cytotherapy. 2009;11(2):153-62.



Miltenyi Biotec provides products and services worldwide. Visit www.miltenyibiotec.com/local to find your nearest Miltenyi Biotec contact. The CliniMACS[®] System components: Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer are manufactured and controlled under an ISO 13485 certified quality system. In Europe, the CliniMACS System components are available as CE-marked medical devices. In the USA, the CliniMACS System components including the CliniMACS Reagents are available for use only under an approved Investigational New Drug (IND) application or Investigational Device Exemption (IDE). CliniMACS[®] MicroBeads are for research use only and not for use in humans. MACS and CliniMACS are registered trademarks or trademarks of Miltenyi Biotec GmbH. Copyright © 2011 Miltenyi Biotec GmbH. All rights reserved.